ArticleBioinformatics (Oxford, England)2026
KG-bench: benchmarking graph neural network algorithms for drug repurposing.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CAREPath: semantic context-aware reasoning paths with mechanism-augmented embeddings for drug repurposing.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationDrug repurposing leverages existing drugs for new indications, accelerating drug development. Computational methods integrating diverse biological and chemical data can systematically prioritize repurposing candidates, but standardized benchmarks for deep learning evaluation are lacking. We present knowledge graph (KG)-Bench, a graph neural network (GNN) benchmarking framework designed to systematically compare the performance of different GNN architectures on drug-disease association prediction using the Open Targets dataset. We constructed a KG of drugs, diseases, and targets, including annotations such as therapeutic area and molecular pathway, and ensured retrospective validation by leveraging regular dataset updates. To avoid data leakage, we removed redundant entities across splits.
resultsBenchmarking six GNN architectures, Relational Graph Convolutional Networks achieved the highest ranking performance (AUC: 0.91), while TransformerConv showed superior robustness under class imbalance (F1: 0.28 at 1:100 positive: negative ratio), characteristic of real drug repurposing datasets. KG-Bench also assesses bias, node/feature importance, and uses GNNExplainer for interpretability. Our open-source framework enables fair, reproducible evaluation of graph-based drug repurposing algorithms. AVAILABILITY AND IMPLEMENTATION: Data and codes are available at https://github.com/cmbi/Benchmark_GNN_OpenTargets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.